BioMed Research International / 2016 / Article / Tab 3

Research Article

A Retrospective Observational Study to Assess Prescription Pattern in Patients with Type B Aortic Dissection and Treatment Outcome

Table 3

Prescribing patterns of nonoperated TBAD patients.

Medication (%) Before index dateAfter index date

-blockers15 (14.2)85 (80.2)
 Selective -blockers9 (8.5)71 (67.0)
  Atenolol3 (2.8)4 (3.8)
  Bisoprolol6 (5.7)68 (64.2)
 Nonselective -blockers4 (3.8)5 (4.7)
  Propranolol4 (3.8)5 (4.7)
- and -blockers5 (4.7)10 (9.4)
  Carvedilol4 (3.8)8 (7.6)
  Labetalol1 (1.0)2 (1.9)
ACEIs/ARBs22 (20.8)54 (50.9)
 ACEIs7 (6.6)7 (6.6)
  Captopril1 (0.9)1 (0.9)
  Fosinopril1 (0.9)1 (0.9)
  Imidapril0 (0)2 (1.9)
  Lisinopril0 (0)1 (0.9)
  Perindopril1 (0.9)1 (0.9)
  Quinapril2 (1.9)0 (0)
  Ramipril4 (3.8)2 (1.9)
 ARBs18 (17.0)49 (46.2)
  Candesartan4 (3.8)15 (14.2)
  Irbesartan7 (6.6)18 (17.0)
  Losartan1 (0.9)5 (4.7)
  Olmesartan6 (5.7)10 (9.4)
  Telmisartan1 (0.9)1 (0.9)
  Valsartan10 (9.4)27 (25.5)
CCBs 25 (23.6)94 (88.7)
 Dihydropyridine22 (20.8)92 (86.8)
  Amlodipine17 (16.0)62 (58.5)
  Felodipine3 (2.8)1 (0.9)
  Lercanidipine2 (1.9)5 (4.7)
  Nicardipine1 (0.9)17 (16.0)
 Nondihydropyridine5 (4.7)7 (6.6)
  Diltiazem4 (3.8)7 (6.6)
  Verapamil1 (0.9)0 (0)
Vasodilator14 (13.2)30 (28.3)
Diuretics16 (15.1)39 (36.8)
-blockers6 (5.7)26 (24.5)
Statins15 (14.2)49 (46.2)
 Atorvastatin12 (11.3)26 (24.5)
 Rosuvastatin5 (4.7)23 (21.7)
 Fluvastatin1 (1.0)4 (3.8)
 Pravastatin3 (2.8)5 (4.7)
Other lipid-lowering agents7 (6.6)14 (13.2)
Antiplatelet agents17 (16.0)39 (36.8)
 Aspirin13 (12.3)34 (32.1)
 Clopidogrel10 (9.4)13 (12.3)
 Dipyridamole4 (3.8)5 (4.7)
Warfarin2 (1.9)2 (1.9)
Antidiabetic agents6 (5.7)18 (17.0)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.